CN106999539A - 腹水的治疗 - Google Patents

腹水的治疗 Download PDF

Info

Publication number
CN106999539A
CN106999539A CN201680003239.1A CN201680003239A CN106999539A CN 106999539 A CN106999539 A CN 106999539A CN 201680003239 A CN201680003239 A CN 201680003239A CN 106999539 A CN106999539 A CN 106999539A
Authority
CN
China
Prior art keywords
terlipressin
ascites
patient
continuous infusion
salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201680003239.1A
Other languages
English (en)
Chinese (zh)
Inventor
P.昂厄利
P.马卡姆
J.阿达姆斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biovie Inc
Original Assignee
Nanoantibiotics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57609113&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN106999539(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Nanoantibiotics Inc filed Critical Nanoantibiotics Inc
Priority to CN202510468211.6A priority Critical patent/CN120324576A/zh
Publication of CN106999539A publication Critical patent/CN106999539A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/095—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Dermatology (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
CN201680003239.1A 2015-06-30 2016-06-30 腹水的治疗 Pending CN106999539A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202510468211.6A CN120324576A (zh) 2015-06-30 2016-06-30 腹水的治疗

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201562186638P 2015-06-30 2015-06-30
US62/186,638 2015-06-30
US201562267510P 2015-12-15 2015-12-15
US62/267,510 2015-12-15
US201662321558P 2016-04-12 2016-04-12
US62/321,558 2016-04-12
PCT/US2016/040284 WO2017004317A1 (en) 2015-06-30 2016-06-30 Treatment of ascites

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202510468211.6A Division CN120324576A (zh) 2015-06-30 2016-06-30 腹水的治疗

Publications (1)

Publication Number Publication Date
CN106999539A true CN106999539A (zh) 2017-08-01

Family

ID=57609113

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202510468211.6A Pending CN120324576A (zh) 2015-06-30 2016-06-30 腹水的治疗
CN201680003239.1A Pending CN106999539A (zh) 2015-06-30 2016-06-30 腹水的治疗

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN202510468211.6A Pending CN120324576A (zh) 2015-06-30 2016-06-30 腹水的治疗

Country Status (7)

Country Link
US (6) US9655945B2 (enExample)
EP (2) EP3347032B1 (enExample)
JP (6) JP2017014206A (enExample)
CN (2) CN120324576A (enExample)
ES (1) ES2971959T3 (enExample)
HK (1) HK1258611A1 (enExample)
WO (1) WO2017004317A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112704727A (zh) * 2021-01-12 2021-04-27 重庆医科大学附属第二医院 特利加压素在制备动力性肠梗阻药物中的应用

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010032140A2 (en) 2008-09-17 2010-03-25 Chiasma Inc. Pharmaceutical compositions and related methods of delivery
PT3978074T (pt) 2014-10-24 2024-05-13 Mallinckrodt Pharmaceuticals Ireland Ltd Terlipressina para tratamento da síndrome hepatorrenal de tipo 1
FI3253401T3 (fi) 2015-02-03 2025-07-09 Amryt Endo Inc Akromegallian hoitaminen suun kautta annettavalla oktreotidilla
JP2017014206A (ja) * 2015-06-30 2017-01-19 ナノアンティバイオティクス，インコーポレイテッド 腹水の治療
MA46586A (fr) 2016-10-21 2019-08-28 Chiasma Inc Compositions de terlipressine et leurs procédés d'utilisation
CN113077888A (zh) * 2021-03-30 2021-07-06 福州宜星大数据产业投资有限公司 自动化meld评分方法、终端及存储介质
JP2025505010A (ja) * 2022-02-03 2025-02-19 バイオビー インコーポレーテッド テルリプレシンを用いた疾患の治療方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002024213A2 (en) * 2000-09-15 2002-03-28 Inserm Improved protocol for paracentesis
US20110300109A1 (en) * 2008-08-26 2011-12-08 Kyon Biotech Ag Compositions and methods for treating cancer
CN102731625A (zh) * 2012-06-27 2012-10-17 深圳翰宇药业股份有限公司 一种纯化特利加压素的方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE027174T2 (en) * 2006-02-13 2016-10-28 Ferring Bv Use of peptide agonists of the vasopressin receptor
EP2175874A2 (en) * 2007-08-14 2010-04-21 Ferring B.V. Use of peptidic vasopressin receptor agonists
US20100311642A1 (en) * 2007-09-28 2010-12-09 Ferring B.V. Use of v2 receptor antagonists in combination with vaso pressinergic agnosts
US20110003890A1 (en) * 2007-11-08 2011-01-06 Jason Joel Schwartz Use of angiogenesis antagonists in conditions of abnormal venous proliferation
ES2661310T3 (es) * 2009-03-09 2018-03-28 Bioatla, Llc Proteínas mirac
EA025735B1 (ru) * 2009-06-08 2017-01-30 ЮСиЭл БИЗНЕС ПиЭлСи Способ лечения портальной гипертензии с использованием l-орнитина в сочетании по меньшей мере с одним из соединений, выбранных из фенилацетата и фенилбутирата
WO2012009545A1 (en) * 2010-07-14 2012-01-19 Cumberland Emerging Technologies, Inc Methods of treating hepatorenal syndrome and hepatic encephalopathy with thromboxane-a2 receptor antagonists
WO2013106072A1 (en) * 2012-01-10 2013-07-18 Sorbent Therapeutics, Inc. Compositions comprising crosslinked cation-binding polymers and uses thereof
JO3109B1 (ar) * 2012-05-10 2017-09-20 Ferring Bv منبهات لمستقبلات v1a
US9091701B2 (en) 2012-11-12 2015-07-28 The Regents Of The University Of Colorado, A Body Corporate Disease severity index for assessment of chronic liver disease and method for diagnosis of three distinct subtypes of primary sclerosing cholangitis
JP6522584B2 (ja) * 2013-04-26 2019-05-29 ラ ホヤ ファーマシューティカル カンパニーＬａ Ｊｏｌｌａ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏｍｐａｎｙ 腎不全を処置するための組成物及び方法
CN104510840A (zh) * 2013-08-21 2015-04-15 乔治亚摄政研究学院有限公司 改性绿茶多酚和其用于治疗肝病的方法
JP2017014206A (ja) * 2015-06-30 2017-01-19 ナノアンティバイオティクス，インコーポレイテッド 腹水の治療

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002024213A2 (en) * 2000-09-15 2002-03-28 Inserm Improved protocol for paracentesis
US20040102362A1 (en) * 2000-09-15 2004-05-27 Didier Lebrec Protocol for paracentesis
US20110300109A1 (en) * 2008-08-26 2011-12-08 Kyon Biotech Ag Compositions and methods for treating cancer
CN102731625A (zh) * 2012-06-27 2012-10-17 深圳翰宇药业股份有限公司 一种纯化特利加压素的方法

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ALEKSANDER KRAG等: ""Terlipressin improves renal function in patients with cirrhosis and ascites without hepatorenal syndrome"", 《HEPATOLOGY》 *
MARCUS ROBERTSON等: ""Continuous outpatient terlipressin infusion for hepatorenal syndrome as a bridge to successful liver transplantation"", 《HEPATOLOGY》 *
PAOLO ANGELI: ""Terlipressin for the treatment of hepatorenal syndrome in patients with cirrhosis"", 《EXPERT OPINION ON ORPHAN DRUGS》 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112704727A (zh) * 2021-01-12 2021-04-27 重庆医科大学附属第二医院 特利加压素在制备动力性肠梗阻药物中的应用
CN112704727B (zh) * 2021-01-12 2023-05-16 重庆医科大学附属第二医院 特利加压素在制备动力性肠梗阻药物中的应用

Also Published As

Publication number Publication date
ES2971959T3 (es) 2024-06-10
CN120324576A (zh) 2025-07-18
JP2018172440A (ja) 2018-11-08
US11364277B2 (en) 2022-06-21
WO2017004317A1 (en) 2017-01-05
JP2023160839A (ja) 2023-11-02
US20230146264A1 (en) 2023-05-11
JP2025143324A (ja) 2025-10-01
JP2022136104A (ja) 2022-09-15
JP2017014206A (ja) 2017-01-19
US20190365848A1 (en) 2019-12-05
US20180000887A1 (en) 2018-01-04
US20240165193A1 (en) 2024-05-23
US20170000844A1 (en) 2017-01-05
EP4338795A2 (en) 2024-03-20
JP2020172520A (ja) 2020-10-22
US20250312410A1 (en) 2025-10-09
EP3347032A1 (en) 2018-07-18
US9655945B2 (en) 2017-05-23
HK1258611A1 (zh) 2019-11-15
EP3347032B1 (en) 2023-11-29
EP3347032A4 (en) 2019-06-19
EP4338795A3 (en) 2024-08-28

Similar Documents

Publication Publication Date Title
CN106999539A (zh) 腹水的治疗
Nakayama et al. Novel therapeutic option for refractory heart failure in elderly patients with chronic kidney disease by incremental peritoneal dialysis
JP2018533589A5 (enExample)
JP2018521964A5 (enExample)
RU2015134581A (ru) Доноры нитроксила с улучшенным терапевтическим индексом
Baeg et al. Management for electrolytes disturbances during continuous renal replacement therapy
JP2025143324A5 (enExample)
JP2018531605A5 (enExample)
JP2020510043A5 (enExample)
CN102552121B (zh) 一种米力农注射液
CN114796246B (zh) 一种用于治疗心力衰竭的药物及其用途
CN104688766B (zh) 注射用藻酸双酯钠粉针剂药物组合物和制法
RU2406539C2 (ru) Способ лечения хронической почечной недостаточности
CN1064234C (zh) 二咖啡酰氧基--奎宁酸在制药中的应用
Qi et al. Altered Mental Status and Hyponatremia After 20 Hours of Amiodarone Therapy
Poca et al. 104 RENAL FAILURE AND MORTALITY IN CIRRHOTIC PATIENTS WITH SPONTANEOUS BACTERIAL PERITONITIS AND LOW RISK OF MORTALITY NON-TREATED WITH ALBUMIN
Knyazkova et al. Efficiency of torasemide in heart failure in patients with ischemic heart disease and chronic obstructive pulmonary disease
US20170007617A1 (en) Intravenous formulations of a late sodium current inhibitor
Alessandria et al. 103 RELATIVE ADRENAL INSUFFICIENCY IN CIRRHOSIS: RELEVANCE IN PATIENTS WITH ASCITES AND TREATMENT WITH HYDROCORTISONE IN REFRACTORY ASCITES
CN104069115B (zh) 依前列醇在制备缓解利尿剂抵抗药物中的用途
CN103285378A (zh) Glp-1用于制备预防与治疗2型糖尿病性心肌病的药物的用途
CN1650849A (zh) 比索洛尔非肠道给药制剂
Li Application of albumin in liver cirrhosis and its complications
JP2018104291A (ja) マグネシウム化合物を有効成分として含有することを特徴とする医薬組成物
JP2016210733A (ja) ガン予防または治療用医薬組成物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination